Table 2. Comparison between the population of enrolled patients with VSPV and the group of VSPV patients to be treated with MPFF.
| Characteristics of patients with VSPV | Enrolled subjects (N = 48) | Men (N = 30) | Women (N = 18) | MPFF group (N = 24) | Men (N = 17) | Women (N = 7) | p-Value |
|---|---|---|---|---|---|---|---|
| Mean age (y) | 51.5 | 53.9 | 47.7 | 55.8 | 54.1 | 56.6 | 0.301 |
| Mean time since thrombotic event (y) | 3.4 | 3.4 | 3.4 | 3.9 | 3.9 | 4.0 | 0.232 |
| Location of dilated VSPV, N (%) | NS | ||||||
| Left side | 22 (46) | 9 (30) | 13 (72) | 11 (46) | 6 (35) | 5 (72) | 1.000 |
| Right side | 7 (15) | 4 (13) | 3 (17) | 3 (12) | 2 (12) | 1 (14) | 0.833 |
| Bilateral | 19 (39) | 17 (57) | 2 (11) | 10 (42) | 9 (53) | 1 (14) | 0.912 |
| Of which, contralateral | 0 | 0 | 0 | 0 | 0 | 0 | |
| Degree of dilation, N (%) | NS | ||||||
| Grade 1 (5–6 mm) | 13 (27) | 10 (33) | 3 (17) | 2 (10) | 1 (50) | 1 (50) | 0.124 |
| Grade 2 (7–9 mm) | 28 (58) | 17 (57) | 11 (61) | 20 (80) | 14 (70) | 6 (30) | 0.353 |
| Grade 3 (≥ 9 mm) | 7 (15) | 3 (10) | 4 (22) | 2 (10) | 2 (100) | 0 (0) | 0.501 |
| Mean diameter, mm (95% CI) | 7.64 (5.47–10.93) | 7.20 (5.03–10.49) | 7.91 (5.44–15.83) | 7.59 (5.04–9.70) | 7.52 (5.04–9.70) | 7.79 (5.83–9.19) | |
| Retrograde blood flow, N (% patients) | 35 (73) | 21 (70) | 14 (78) | 16 (67) | 12 (71) | 4 (57) | 0.819 |
Abbreviations: CI, confidence interval; MPFF, micronized purified flavonoid fraction; VSPV, varicose small pelvic veins.